​

Aerovate Therapeutics Stock (NASDAQ:AVTE)

ForecastRevenueOwnershipFinancialsChart
Aerovate Therapeutics by TradingView

Previous Close

$2.53

52W Range

$1.25 - $32.41

50D Avg

$2.50

200D Avg

$9.35

Market Cap

$73.05M

Avg Vol (3M)

$772.68K

Beta

1.00

Div Yield

-

AVTE Company Profile

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

51

IPO Date

Jun 30, 2021

Website

AVTE Performance

AVTE Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-81.41M$-53.24M$-23.02M
Net Income$-75.52M$-51.51M$-22.96M
EBITDA$-81.31M$-53.17M$-23.01M
Basic EPS$-2.87$-2.10$-1.87
Diluted EPS$-2.87$-2.10$-1.87

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ANTXAN2 Therapeutics, Inc.
MLYSMineralys Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
RZLTRezolute, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
OPTOpthea Limited